Jiang G et al. |
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. |
2015 |
PLoS Pathog. |
pmid:26225771
|
Freiberger SN et al. |
Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. |
2015 |
Mol. Cancer Ther. |
pmid:26116359
|
Soini EJ et al. |
Cost-utility of first-line actinic keratosis treatments in Finland. |
2015 |
Adv Ther |
pmid:26006101
|
Cantisani C et al. |
Evaluation of Ingenol mebutate efficacy for the treatment of actinic keratosis with Antera 3D camera. |
2015 |
Eur Rev Med Pharmacol Sci |
pmid:25635981
|
Edwards SK et al. |
N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma. |
2013 |
BMC Cancer |
pmid:24131623
|
Song X et al. |
RasGRPs are targets of the anti-cancer agent ingenol-3-angelate. |
2013 |
PLoS ONE |
pmid:23991094
|
Cozzi SJ et al. |
Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. |
2013 |
Arch. Dermatol. Res. |
pmid:22871992
|
Liang X et al. |
Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer. |
2013 |
Bioorg. Med. Chem. Lett. |
pmid:23993332
|
Doan HQ et al. |
Ingenol mebutate: potential for further development of cancer immunotherapy. |
2012 |
J Drugs Dermatol |
pmid:23134979
|
Lebwohl M et al. |
Ingenol mebutate gel for actinic keratosis. |
2012 |
N. Engl. J. Med. |
pmid:22417254
|
Fallen RS and Gooderham M |
Ingenol mebutate: an introduction. |
2012 |
Skin Therapy Lett. |
pmid:22358305
|
Cozzi SJ et al. |
Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. |
2012 |
J. Invest. Dermatol. |
pmid:22189786
|
Lee WY et al. |
Novel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase Ctheta. |
2010 |
J. Biol. Chem. |
pmid:20472553
|
Li L et al. |
The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. |
2010 |
Cancer Res. |
pmid:20460505
|
Ghoul A et al. |
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. |
2009 |
Cancer Res. |
pmid:19417139
|
Benhadji KA et al. |
Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. |
2008 |
Br. J. Cancer |
pmid:19034280
|
Serova M et al. |
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. |
2008 |
Mol. Cancer Ther. |
pmid:18413805
|
Challacombe JM et al. |
Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. |
2006 |
J. Immunol. |
pmid:17114487
|
Cozzi SJ et al. |
Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. |
2006 |
Cancer Res. |
pmid:17047072
|
Hampson P et al. |
PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. |
2005 |
Blood |
pmid:15845901
|